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1  | INTRODUC TION
Pediatric patients embarking on genetic diagnostic odysseys often 
have complex medical needs and their primary care physicians 
(PCPs) play critical care roles by serving as the medical home that 
coordinates their long‐term multipart management plans (Genetics 
in Primary Care, 2018; Lantin‐Hermoso et al., 2017). As new genetic 
testing technology is developed and increasingly implemented, PCPs’ 
responsibilities for these patients and their families will continue to 
grow and proper patient care will depend on appropriate levels of 
genetic literacy and collaboration with genetics healthcare providers 
(GHP), clinical specialists who evaluate, diagnose, and provide infor‐
mation and recommendations regarding genetic conditions.
The introduction of exome sequencing (ES) as a diagnostic 
test has provided diagnoses to many pediatric patients who had 
exhausted all other genetic test options (Biesecker & Biesecker, 
2014; Iglesias et al., 2014; Lazaridis et al., 2016; Lee et al., 2014; 
Sawyer et al., 2016). With a diagnostic rate ranging from 20%–
34%, compared to that of chromosomal microarray (CMA) at 12%–
22%, the clinical usefulness and diagnostic value of ES in certain 
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Abstract
Optimizing exome sequencing (ES) utility requires effective communication and 
collaboration between primary care physicians (PCPs) and genetics healthcare pro‐
viders (GHP). To explore how PCPs use ES results to coordinate multipart manage‐
ment plans for complex pediatric patients, we assessed result understanding and 
utilization. Twenty‐seven PCPs of pediatric patients with ES results from a genetics 
clinic completed a mixed methods 45‐question survey measuring perceived genet‐
ics knowledge, confidence performing genetics tasks, understanding of ES technol‐
ogy and results, and expectations of GHP. Quantitative and qualitative data analysis 
classified by ES result types generated descriptive statistics, Pearson correlation co‐
efficients, and common themes. Forty‐five‐percent of PCPs interpreted variant of 
uncertain significance results as diagnostic (implementing management changes and 
recommending familial testing). Most PCPs (85%) identified positive ES results im‐
pacts, but only 65% indicated ES was beneficial to care. The majority (74%) expected 
GHP and patients’ families to assume follow‐up care responsibility and future ES 
results re‐interpretations. Limited knowledge may be a factor, as 59% desired more 
patient care information from GHP. Our results suggest optimizing continuity of care 
and collaboration for pediatric patients with ES results requires additional communi‐
cation between GHP and PCPs, along with continuing genetics education for PCPs 
aimed at improving genetic literacy.
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pediatric populations is clear (Battaglia et al., 2013; Biesecker 
& Biesecker, 2014; Coulter et al., 2011; Henderson et al., 2014; 
Iglesias et al., 2014; Lazaridis et al., 2016; Lee et al., 2014; Miller 
et al., 2010; Sawyer et al., 2016). Although useful, this complex 
genetic test has resulted in novel challenges, ranging from variant 
interpretation to determining management for novel conditions, 
for GHP who order the test and PCPs who receive their patients’ 
results (Biesecker & Biesecker, 2014; Iglesias et al., 2014; Lee et 
al., 2014; Nguyen & Charlebois, 2015; Tetreault, Bareke, Nadaf, 
Alirezaie, & Majewski, 2015).
In order to utilize the various complicated possible genetic 
testing results, PCPs need to maintain a sufficient understanding 
of genetics to ensure proper implementation and communication 
of recommendations regarding test results from GHP into their 
patient's everyday care. PCPs have reported limited general ge‐
netics knowledge and skills along with shortcomings related to 
confidence, comfort, and ability to perform specific genetics re‐
lated tasks (Mikat‐Stevens, Larson, & Tarini, 2015). Furthermore, 
while a subset of PCPs indicated that genetics evaluations were 
useful for their patients, only approximately half of these PCPs 
felt competent to provide healthcare for patients related to ge‐
netics following their genetics evaluations (Rinke et al., 2013). This 
perspective was mirrored by patient reports ranking their PCPs’ 
overall genetics knowledge as poor (Harvey et al., 2007). As pe‐
diatric genetics patients often present with multiple physical and 
cognitive differences, PCPs low reported genetics knowledge and 
lack of confidence in their abilities to provide care that is informed 
by genetics results can be detrimental to the continuous manage‐
ment and care for these patients.
Continuity of care is essential for pediatric genetics patients as 
they maintain care with their medical home, the PCPs, following a 
limited number of genetics appointments. The American Academy 
of Pediatrics Council on Children with Disabilities acknowledges 
several barriers to effective care coordination of PCPs as the medi‐
cal home: lack of knowledge and information, lack of communication 
among healthcare professionals, and lack of clearly defined roles for 
each member of the practice team (American Academy of Pediatrics 
Council on Children with Disabilities, 2005). Consequently, in order 
to improve patient care, it is critical to identify ways to promote com‐
munication and collaboration between PCPs and GHP. This study 
assessed PCPs’ understanding and utilization of ES results in the 
management of their pediatric patients and families with an objec‐
tive of improving continuity of care for pediatric genetics patients 
by identifying areas to improve communication and collaboration 
between PCPs and GHP.
2  | METHODS
2.1 | Participants
We recruited PCPs whose patient received an ES test result or‐
dered by the University of Michigan Health Services– Division 
of Pediatric Genetics between February 2013 and October 2016 
(n = 308). To increase PCP's survey responses’ specificity, the fol‐
lowing patients/PCPs were excluded: three or more variants de‐
tected by ES (n = 40), GHP reinterpreted the laboratory reported 
result (n = 2), deceased (n = 2), and more than one patient with 
an ES result for a single PCP (n = 50). We prioritized inclusion of 
patients from negative and pathogenic variant result groups to at‐
tempt recruitment of an equal number of PCPs for each ES result 
type. A total of 214 PCPs were mailed a recruitment letter that 
included the ES result with the laboratory report interpretation 
on their named patient, and a link to an online survey. This study 
was approved by the University of Michigan Institutional Review 
Board (HUM00118547).
2.2 | Instrumentation
To assess PCPs’ knowledge about and use of ES results in their 
patients’ care, we developed a mixed methods study instrument 
including modified questions from validated instruments that evalu‐
ated PCPs’ perspectives and understanding of genetics, ES in gen‐
eral, and applying genetic test results to patient's care (Data S1; Jez, 
Martin, South, Vanzo, & Rothwell, 2015; Pearl et al., 2011; Reiff et 
al., 2015; Rinke et al., 2013; Saam, Gudgeon, Aston, & Brothman, 
2008). The 45‐question instrument focused on five domains: physi‐
cian demographics (6 questions), self‐assessed genetics knowledge 
and confidence (14 questions), understanding of ES results (6 ques‐
tions), patient and family healthcare management (6 questions), 
communication with patients and their families (3 questions), and 
collaboration with GHP (10 questions). Response options included 
5‐point Likert scales that assessed PCP's genetics knowledge (1: 
none/minimal, 2: basic, 3: proficient, 4: advanced, 5: superior) and 
confidence performing genetics related tasks (discussing or making 
genetics referrals, discussing or ordering genetic testing, interpret‐
ing or communicating genetic testing results; 1: very uncomfortable 
to 5: very comfortable), as well as true/false, select all that apply, and 
free response questions to assess participants’ understanding of ES 
results, communication with patients and families, and collaboration 
with GHP. The first question asked the PCP to identify their patient's 
result (pathogenic variant, variant of uncertain significance (VUS), 
negative) and to disregard any incidental findings. Participants pro‐
vided informed consent prior to completing the survey. Prior to fi‐
nalization, the instrument was piloted with a pediatric geneticist, 
a pediatric genetics resident, and an otolaryngologist who had re‐
ceived an ES patient result.
2.3 | Data analysis
Quantitative analysis using descriptive statistics, ANOVA, and 
Pearson correlation coefficients was completed using R software 
with the help of statistical consultants at the University of Michigan 
Center for Statistical Consultation and Research. Likert scale ques‐
tions for genetics knowledge and confidence were analyzed individ‐
ually and summed to generate separate knowledge and confidence 
scores for each PCP. Qualitative analysis of open text responses 
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were completed by three team members utilizing structural and 
descriptive coding methods to identify common themes (Saldaña, 
2013). An error in survey administration led to partial survey com‐
pletion by one respondent. This respondent's results are included in 
the data analysis for the completed portions and results for relevant 
sections reflect this variation in participant numbers. ES results were 
defined as either “laboratory reported result” for the laboratory is‐
sued report or “PCP reported result” for the PCP's survey response. 
Analyses based on result type utilized PCP reported results.
3  | RESULTS
3.1 | PCP demographics
Of the 214 recruited PCPs (laboratory reported results: 51 with 
pathogenic variant, 18 with pathogenic variant and VUS, 94 with 
VUS, 51 with negative results), 27 PCPs responded (laboratory re‐
ported results: 9 with pathogenic variant, 14 with VUS, 4 with nega‐
tive results). Each participating PCP provided responses based on a 
single patient result. The overall response rate was 12.6%. Among 
the 27 responding PCPs, the majority (63%) of PCPs have been in 
practice for more than 10 years and for 9/27 (33%) their last genet‐
ics training was 10+ years ago (Figure 1). Additionally, 7/27 (26%) 
PCPs’ last genetics training was in medical school, and from those, 
6/7 (86%) of these PCPs’ medical school training was 10+ years ago.
To assess respondents’ genetics understanding, PCPs self‐rated 
their knowledge of eight genetics subjects and comfort perform‐
ing genetics related tasks. The mean totaled genetics knowl‐
edge scores for respondents was 23.2 (range = 16–38; Table 1). 
All respondents indicated that they were somewhat comfort‐
able or very comfortable discussing and making referrals to GHP 
(mean = 8.9, range = 8–10). The mean self‐assessed comfort score 
performing genetic testing‐related tasks was 12.9 (range = 8–19). 
We found participants with higher knowledge scores were more 
likely to have higher comfort scores for performing genetics refer‐
ral tasks (r = .54, p = .003) and genetic testing related tasks (r = .69, 
p = <.001). We found that those practicing as PCPs for shorter 
time periods were more likely to have higher knowledge scores 
(r=−.41, p = .034) and higher comfort performing genetic testing 
tasks scores (r = −.25, p = .218). PCPs who attended a more recent 
genetics training were also more likely to have higher knowledge 
scores (r = −.42, p = .029) and higher comfort performing genetic 
testing tasks scores (r = −.59, p = .001). One‐way ANOVA analysis 
did not identify any statistically significant differences between 
ES result type and knowledge scores (F(2,24) = 2.918, p = .073), 
comfort performing referrals to GHP scores (F(2,24) = 0.691, 
p = .511), or comfort performing genetic testing‐related tasks 
scores (F(2,24) = 1.503, p = .243).
3.2 | Understanding of ES test results
To assess PCPs’ understanding of their patient's genetic results, they 
were asked to state what type of ES result their patient received. Of 
the 27 respondents (PCP reported results: 10 with pathogenic vari‐
ant, 12 with VUS, 5 with negative results), most PCPs (93%) correctly 
identified their patient's ES result type. However 2/14 PCPs (14%) 
incorrectly reported their patients’ VUS results: one PCP indicated 
that their patient received a pathogenic result, and the other a nega‐
tive result. For these two study participants, subsequent responses 
were evaluated according to ES result type they indicated for their 
patient.
PCPs shared their perspectives on the impact of ES on their pa‐
tient's care (Table 2). The majority of PCPs overall (17/26, 65%) and 
of each result type group (pathogenic 8/10, 80%; VUS 6/11, 55%; 
negative 3/5, 60%) agreed with the statement that ES was beneficial 
to their patient's care. To deepen our understanding of the PCPs’ 
views of ES, all PCPs were asked to identify the most and least ben‐
eficial outcomes of receiving ES test results. Of the 22 PCPs who 
provided reasons, 24 benefits were identified overall and condensed 
into four themes: (a) family emotional support (12/24, 50%), (b) iden‐
tifying a genetic diagnosis (6/24, 25%), (c) ruling out a genetic diagno‐
sis (3/24, 13%), and (d) providing medical management (3/24, 13%). 
Of the 23 PCPs who identified unfavorable outcomes, 27 outcomes 
were provided and condensed into four themes: (a) inability to alter 
F I G U R E  1   Legend: Demographic 
information of Primary Care Physicians 
(PCPs) divided by years of experience 
practicing as a PCP and by the timing of 
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management (11/27, 41%), (b) not receiving a genetic diagnosis (7/27, 
26%), (c) receiving uncertain results (5/27, 19%), and (d) perceived fi‐
nancial burden (4/27, 15%). Although most PCPs could identify both 
benefits and limitations of ES for their patient and their family, 3/11 
(27%) PCPs with VUS results were unable to identify why ES was 
beneficial for their patient while 2/10 (20%) PCPs with pathogenic 
results were unable to identify any negative connotations of ES for 
their patient.
To understand how the study participants looked at the ES 
test results within the context of their patient's diagnostic odys‐
sey, respondents indicated their views on how ES results impacted 
their patients’ ongoing care (Table 2). PCPs with pathogenic re‐
sults (9/10, 90%) were more likely to agree with the statement 
that the ES result explains some or all of their patient's symptoms, 
than PCPs with VUS results (5/11, 45.5%). The remaining PCPs 
with VUS results agreed instead with the statement that ES re‐
sults may explain their patient's symptoms (5/11, 45.5%) or the 
ES result does not explain their patient's symptoms (1/11, 9%). 
Additionally, PCPs with pathogenic results were more likely to 
agree with the statements that there is a genetic cause for their 
patient's symptoms and the ES results will be reanalyzed in the fu‐
ture, than PCPs with VUS or negative results, while the minority of 
PCPs in each result group indicated that there will be more genetic 
testing in the future for their patient (Table 2).
3.3 | Utilization of ES results in patient/
family healthcare
To determine how PCPs used ES results in the medical manage‐
ment of their patients, PCPs described what, if any, changes were 
made. Ten of twenty‐six (38%) PCPs changed management for 
their patient after receiving the ES result (Table 2). PCPs made a 
total of 24 management changes for 10 patients. Nine manage‐
ment changes (9/24, 38%) related to patient medical care: medi‐
cal screenings (4/9, 44%), referral to a specialist (3/9, 33%), new 
medication regimes (2/9, 22%), while no one discontinued previ‐
ously recommended screening. Fifteen management changes 
(15/24, 63%) related to family support: family testing for reproduc‐
tive reasons (4/15, 27%), family testing for medical reasons (4/15, 
27%), recurrence risk for the family (4/15, 27%), and improved 
Assessment statements






(n = 5) All results
ES result explains some or all symptoms 9/10 (90%) 5/11 (45%) — 14/21 (67%)b
There is a genetic cause for my pa‐
tient's symptoms
9/10 (90%) 7/11 (64%) 1/5 (20%) 17/26 (65%)
PCPs encouraging discussion of results 
with family members
8/10 (80%) 8/11 (73%) 2/5 (40%) 18/26 (69%)
ES was beneficial to care 8/10 (80%) 6/11 (55%) 3/5 (60%) 17/26 (65%)
Management changes made 7/10 (70%) 3/11 (27%) 0/5 (0%) 10/26 (38%)
ES results will be reanalyzed in the 
future
6/10 (60%) 4/11 (36%) 1/5 (20%) 11/26 (42%)
More genetic testing in the future 2/10 (20%) 5/11 (45%) 2/5 (40%) 9/26 (35%)
Note: Data presented in this table (Percentages) indicate the number of participants in each ES 
result category that agreed with the assessment statement. “n” in each column equals the number 
of PCPs with the PCP reported result type.
aOnly 11 of the 12 PCPs with VUS results responded to this set of questions. 
bOnly PCPs with pathogenic and VUS results responded to this question. 
TA B L E  2   Primary care physicians 
(PCPs) perspectives on utility of exome 
sequencing results in patient care
TA B L E  1   Primary care physicians genetics knowledge and confidence performing genetics tasks
Assessment domain
Type of exome sequencing result received
Pathogenic (n = 10) VUS (n = 12) Negative (n = 5) All Results (n = 27)
Genetics knowledge score (Possible range 8–40) 25.3 (16–33) 23.6 (16–38) 17.8 (16–19) 23.2 (16–38)
Confidence performing genetics referral tasksa 
(Possible range 2–10)
9.1 (8–10) 8.8 (8–10) 8.6 (8–10) 8.9 (8–10)
Confidence with genetic testing tasksb (Possible 
range 4–20)
14.1 (8–19) 12.8 (9–18) 11.0 (8–16) 12.9 (8–19)
Note: Means are displayed with the reported range in parentheses following. “n” in each column equals the number of PCPs with the PCP reported 
result type.
aGenetics referral tasks include discussing or making referrals to genetics. 
bGenetic testing tasks include discussing or ordering genetic testing and interpreting or communication genetic test results. 
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access to services for the family (3/15, 20%). From the manage‐
ment changes made, 3 PCPs with VUS results made 46% (11/24) 
of the management changes. Management changes made by the 
PCPs based on ES results was not correlated with the self‐reported 
genetics knowledge scores or comfort performing genetics related 
tasks scores. We were not able to identify a correlation between 
patients’ clinical presentations and management changes made by 
PCPs due to medical complexity.
To further classify ES result management implications, PCPs 
described their interactions with the patients’ families. The ma‐
jority of all PCPs (18/26, 69%) and of pathogenic (8/10, 80%) and 
VUS (8/11, 73%) subgroups indicated that they encouraged or will 
encourage their patient's parents to discuss their child's genetic 
testing results with other family members (Table 2). Among these 
18 providers, the rationale for encouraging family conversations 
included: important information for the family to know (13/18, 
72%), providing/receiving support (11/18, 61%), acceptance and 
understanding of the child (10/18, 55%), help processing the in‐
formation provided by healthcare professionals (8/18, 44%), and 
advice (4/18, 22%).
3.4 | Provider expectations and needs
To assess PCP experiences with GHP, PCPs described their commu‐
nication with GHP and views of follow‐up responsibilities (Table 3). 
Only 11/27 (41%) PCPs reported receiving sufficient information 
from GHP to properly manage and counsel their patients and fami‐
lies (Table 3). Among the 59% (16/27) who felt they did not receive 
sufficient information from GHP, half (8/16) wanted more informa‐
tion or a plan from GHP. Three of these eight PCPs had patients 
with negative results and requested more information on ES test‐
ing methodology. The remaining five PCPs with variants detected 
requested more communication and information regarding manage‐
ment of the patient and family. Of the other eight PCPs who did not 
receive sufficient information, five PCPs indicated that they never 
received the ES results and two did not specify the types of addi‐
tional information they required. One PCP with a negative result 
stated that “I don't think that this [genetics information] should be 
put on the primary care provider.”
Primary care physicians were asked about their expectations for 
their patient's follow‐up care and responsibilities of the PCP, GHP, 
and the patient's family (Table 3). The majority of PCPs agreed with 
the statements that their patient will receive follow‐up care from 
GHP (20/27, 74%), GHP will update the patient and their family 
with new information about the ES result as it becomes available 
(19/27, 70%), and GHP will update the PCP with new information 
about the ES result as it becomes available (15/27, 56%). More PCPs 
agreed that it is the family's responsibility (20/27, 74%), rather than 
the PCP's responsibility (12/27, 44%) to follow‐up with GHP about 
new ES result information as it becomes available. Similar numbers 
of PCPs agreed that it is the family's responsibility (17/27, 63%) and 
the PCP's responsibility (16/27, 59%) to follow‐up with GHP about 
the patient's medical care.
4  | DISCUSSION
This study highlights areas where communication and collaboration 
between PCPs and GHP can be strengthened to improve continuity 
of care for genetics patients.
Communication expectations
Type of exome sequencing (ES) result received
Pathogenic 





Patient will receive follow‐up 
care from GHP
8/10 (80%) 10/12 (83%) 2/5 (40%) 20/27 (74%)
GHP will update the pa‐
tient with new ES result 
information
8/10 (80%) 9/12 (75%) 2/5 (40%) 19/27 (70%)
GHP will update the PCP with 
new ES result information
6/10 (60%) 8/12 (67%) 1/5 (20%) 15/27 (56%)
PCP received sufficient infor‐
mation from GHP to properly 
manage and counsel patient
4/10 (40%) 6/12 (50%) 1/5 (20%) 11/27 (41%)
Responsibility to follow‐up with GHP about new ES result information
Family's responsibility 6/10 (60%) 10/12 (83%) 4/5 (80%) 20/27 (74%)
PCP's responsibility 6/10 (60%) 5/12 (42%) 1/5 (20%) 12/27 (44%)
Responsibility to follow‐up with GHP about patient's medical care
Family's responsibility 7/10 (70%) 8/12 (67%) 2/5 (40%) 17/27 (63%)
PCP's responsibility 6/10 (60%) 8/12 (67%) 2/5 (40%) 16/27 (59%)
Note: Data presented in this table (Percentages) indicate the number of participants in each ES 
result category that agreed with the assessment statement. “n” in each column equals the number 
of PCPs with the PCP reported result type.
TA B L E  3   Primary care physicians 
(PCPs) experiences with genetic 
healthcare providers (GHP)
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4.1 | Medical home
The Genetics in Primary Care Institute, an American Academy of 
Pediatrics Health Initiative, identifies providing a medical home 
as one of seven key roles a PCP maintains for genetics patients 
(Genetics in Primary Care, 2018). As the medical home, the PCP 
provides important continuous, accessible, and comprehensive fam‐
ily‐centered care coordination for genetics patients with complex 
healthcare management plans, including a responsibility of discuss‐
ing results as they are returned from specialists (American Academy 
of Pediatrics Council on Children With Disabilities, 2005; Genetics 
in Primary Care, 2018; Medical Home Initiatives for Children With 
Special Needs Project Advisory Committee & American Academy 
of Pediatrics, 2002). PCPs are also being encouraged to incorporate 
genetics roles into their regular care and management of pediatric 
patients, including communication with families, making appropri‐
ate referrals, and managing care (Scott, & Trotter, 2013). This broad‐
ened role for PCPs is greatly needed as genetic medicine continues 
to grow and the GHP shortage continues. Support for this expand‐
ing role stems in part from the difficulty PCPs and patients face 
in gaining access to genetics clinics (Tarini, Zikmund‐Fisher, Saal, 
Edmondson, & Uhlmann, 2015). Additional barriers to GHP, includ‐
ing clinic locations, long wait times, GHP shortage, and insurance 
coverage of tests, may also be impacting PCPs’ willingness to both 
refer patients to GHP and to take on additional genetics responsi‐
bilities in their clinics (Mikat‐Stevens et al., 2015; Tarini et al., 2015; 
Tetreault et al., 2015).
Primary care physicians appear comfortable discussing the im‐
portance of ES results, with 69% of PCPs encouraging patients’ par‐
ents to discuss ES results with family. PCPs’ willingness to discuss 
results importance with patients’ parents may be due to their under‐
standing of the clinical utility of ES for their patients and the rele‐
vance of results that are reported (Nguyen & Charlebois, 2015). Our 
results deepen understanding of PCPs’ needs and indicate they look 
to GHP to communicate results and management directly with the 
family versus coordinating through the PCP as medical home. This 
suggests that involvement and collaboration of multiple providers, 
GHP and PCP, are needed to create an informed medical home to 
support and manage the patient.
4.2 | Genetic technology
With rapid genetic testing technology development, literature 
suggests that PCPs anticipate genome sequencing (GS) reaching 
clinical utility in the near future (Vassy et al., 2015). Advancing 
technology will require PCPs to develop understanding of the 
types of genetic tests utilized by GHP and the potential types of 
results received. This will be challenging as PCPs still lack under‐
standing of ES technology and results. While recent literature de‐
scribes PCPs’ and cardiologists’ views of an inevitable clinical use 
of GS, the minority of PCPs in the negative and VUS groups in our 
study indicated that future genetic testing would occur (Vassy et 
al., 2015). This suggests that our participants may view ES as the 
last possible genetic test for patients either currently or while fail‐
ing to consider future test developments, such as clinical use of 
GS. Additionally, our results suggest that PCPs believe if ES does 
not discover a diagnosis, no underlying genetic etiology for the 
patient's symptoms exists, as most PCPs with negative results in‐
dicated that there is not a genetic cause for their patient's symp‐
toms. These results suggest that PCPs may not fully understand 
the ES technology, what the next steps for their patients’ diagnos‐
tic analysis may be, and how new genetic tests could be utilized in 
the future.
Although we found that PCPs may not completely understand 
ES technology, the majority found ES beneficial to their patient's 
care and identified positive impacts of ES results, suggesting that 
they recognize the clinical utility of ES and see the benefits of ES 
for the majority of patients, regardless of result type. A recent 
study found that with the implementation of GS in clinical care, 
PCPs want to be able to explain GS results to patients and families, 
but were concerned about their lack of general genomic knowl‐
edge hindering their ability to manage this aspect of their patient's 
care (Christensen et al., 2016). A complementary study indicated 
PCPs recognize they have practical issues implementing ES in their 
clinic due to discomfort interpreting the many possible ES results 
(Nguyen & Charlebois, 2015). As new genetic testing technology 
with increasingly complex results is implemented in patient care, 
PCPs will need to continue obtaining appropriate understanding 
of current clinical genetic testing, including clinical utility, test im‐
plications, and potential results.
4.3 | Genetics education
The increasing pressure to take on genetics related roles in primary 
care is concerning as the last genetics training for 33% of the PCPs 
in our study was 10+ years ago, before ES was incorporated into 
clinical practice. The PCPs in our study also self‐reported genetics 
knowledge of an average score of 23.2 in a range of 8–40. Recent 
efforts to enhance PCP genetics education and reforms of medical 
school genetics training may be taking effect, as we found that PCPs 
with more recent genetics trainings showed higher genetics knowl‐
edge scores and confidence scores (Dhar, Alford, Nelson, & Potocki, 
2012; Hagiwara, 2017; Plunkett‐Rondeu, Hyland, & Dasgupta, 2015; 
Vassy et al., 2014). However, since the minority of PCPs in our study 
were assuming responsibility for follow‐up patient care and updating 
ES result information, there is still a need for ongoing genetics edu‐
cation in PCP clinical practice to address advances in genetics to as‐
sist with PCP confidence in follow‐up care. This deficit is especially 
important in light of the increasing accessibility to genetic testing 
outside of clinical settings (Powell et al., 2012). In total, our results 
are consistent with previous studies and suggest that continuing ge‐
netics education for PCPs is key to improving genetic literacy, confi‐
dence performing genetics tasks, and continuity of care for pediatric 
genetics patients. On‐going research assessing implementation of 
genetics education into primary care is necessary to optimize the 
process and ensure highest quality genetics‐based care.
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4.4 | Clinic communication
Parents have previously reported receiving inconsistent or misleading 
information regarding their child's CMA report due to interactions with 
multiple healthcare providers, sometimes including differing interpre‐
tations of results (Reiff et al., 2012). Applying this finding to ES high‐
lights that regular communication between GHP and PCPs is needed 
to facilitate consistent genetic test result explanations. Without this 
consistent understanding, ES results, especially VUS, can be prob‐
lematic for providers and families processing new information about 
a possible diagnosis. Our data adds to this concern with 45% of PCPs 
with VUS results interpreting them as diagnostic for their patients, 
stating results explained their patients’ symptoms and recommending 
additional familial genetic testing based on a VUS result. Furthermore, 
two PCPs incorrectly identified that their patients received VUS re‐
sults even though they were provided with the result type clinical 
documentation from genetics and in the recruitment letter. This is no‐
table as VUS results are considered uninformative for clinical decision 
making and should not guide patient care per American College of 
Medical Genetics and Genomics guidelines, though clinical judgement 
is used by individual GHPs when reviewing VUS results (Richards et 
al., 2015). ES complexity requires open conversation and partnership 
between PCPs and GHP to ensure consistent and accurate informa‐
tion is presented for appropriate patient care.
As 59% of the PCPs stated that they needed more information 
from GHP in order to properly manage and counsel their patients, 
additional importance should be placed on communication from 
GHP to PCPs. Often a single clinic letter serves as communication 
from GHP to both the patient and provider with education of genetic 
test results and medical recommendations (VandenBoom, Trepanier, 
& Carmany, 2018). While guidelines exist for writing GHP letters to 
patients, guidelines for provider‐provider letter communication are 
lacking (Baker, Eash, Schuette, & Uhlmann, 2002). A recent study on 
this topic concluded that patients appreciated short, straightforward, 
and simple letters; this contrasts with healthcare professionals com‐
ments on the usefulness of lengthy and detailed letters (Roggenbuck 
et al., 2015). This aligns with requests from the eight PCPs who indi‐
cated they wanted more information, either on ES testing methodol‐
ogy or regarding management of the patient and family.
4.5 | Study limitations
In the absence of a validated instrument specific to our research 
questions, our study utilized one developed specifically for this 
research. It contained modified questions derived from validated 
instruments and was piloted with medical professionals of vary‐
ing levels of expertise. The small sample and unequal numbers of 
result types from a low response rate make respondent bias pos‐
sible, though variability is present in the received responses sug‐
gesting this pool provides sufficient diversity to identify a number 
of critical factors in how pediatric ES results are used. Additional 
impacting factors include PCP recruitment from a single institu‐
tion and responding PCPs with possibly greater interest in genetics 
and therefore more genetics/ES knowledge than PCPs in general. 
Results could also be impacted by alternate clinical models and 
types of collaborative care. Due to small sample size, we were un‐
able to evaluate confounding factors affecting PCPs with negative 
results, who trended toward lower knowledge and confidence. We 
chose to focus on PCPs in order to maintain clinical consistency 
and specialists’ perspectives could differ. As this work was con‐
ducted with communication relying on the electronic medical re‐
cord system, it was surprising that five PCPs indicated that they do 
not recall receiving their patient's result. This may have influenced 
the accuracy of this study, though we do not believe that the PCPs 
did not have access to the results as the electronic medical records 
provide the ability to obtain the result and documentation of result 
communication. Lastly, this study depended on participant recall 
which may differ from actual outcomes.
4.6 | Practice implications
This study's results emphasize areas to consider when GHP and 
PCPs communicate regarding shared patients. Our results indicate 
PCPs look to GHP to communicate results and management follow‐
up directly with the family versus coordinating through the PCP 
and suggest that PCPs may not fully understand the next steps or 
possibility of future test developments for their patient's diagnos‐
tic odyssey. As new genetic technology is implemented in patient 
care, PCPs will need to continue expanding their understanding of 
current genetic testing and GHP will need to help educate PCPs 
regarding advances. PCPs want more information from GHP and 
additional importance should be placed on ensuring clear, consist‐
ent, and regular communication of information and interpretations 
between GHP and PCPs. PCPs will continue to serve as the medical 
home and GHP need to ensure that sufficient information is pro‐
vided to the PCPs for the long‐term management of their patients.
4.7 | Research recommendations
While PCPs receive genetics education in medical school, contin‐
ued research on implementing and assessing genetics education in 
primary care is necessary to identify the optimal way to convey up‐
dated information regarding genetics into PCP practice. Additionally, 
as PCPs are requesting additional information from GHP for patient 
management, research evaluating how to improve communication be‐
tween GHP and PCP is needed. This will provide guidance to GHP for 
ways of improving communication with providers that will improve 
patient collaborative care. This research would have an impact on care 
and management of patients evaluated by GHP in their medical home, 
especially as testing technology grows in accessibility and complexity.
5  | CONCLUSION
Optimizing ES utility requires effective communication and collabo‐
ration between PCPs and GHP. We assessed PCPs’ understanding 
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and utilization of ES results in pediatric patient management. 
Challenges in utilization of ES results and ongoing development of 
genetic technologies require strong communication between PCPs 
and GHP in order to ensure continuity of care for pediatric genetics 
patients. Our results suggest that PCPs are open to this interaction 
and highlight opportunities to improve genetic literacy, collaboration 
with GHP, and continuity of care for pediatric genetics patients.
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